USCOM LIMITED — Capital/Financing Update 2017

Jul 16, 2017

ASX MEDIA RELEASE

Uscom BP+ Distributor for SE Asia

Appointment of established partner to distribute BP+ and BP+ Reporter in SE Asia

SYDNEY, Australia, Monday 17[th] July 2017: Uscom Limited (ASX code: UCM) (the Company or Uscom ) announced a distribution agreement for the Uscom BP+ and BP+ Reporter with Pacific Medical Systems Limited (PMS) of Hong Kong. The three year agreement covers distribution into Thailand, Hong Kong and Macau, Singapore, Taiwan, Malaysia and Indonesia

Key Points

• The Uscom BP+ is practice changing suprasystolic oscillometric technology for central blood pressure monitoring and central pulse pressure wave analysis

• The BP+ Reporter is the proprietary stand-alone software solution that provides a digital platform to archive patient examinations and images, display trend measures over time, analyse blood pressure waveforms and values, and generate patient reports.

• PMS are master medical device distributors with many years regional expertise in China and SE Asia with specific skills in bringing new medical technologies to market

• PMS are long term Uscom partners, having introduced USCOM 1A on its release, and currently distribute USCOM 1A through China, Taiwan, Korea and SE Asia

• The BP+ agreement covers countries with a combined population of 393M (Aprox 5% of world pop)

• • Best intentions BP+ and BP+ Reporter targets are for approximately AU$1.5M sales revenue over 3 years following regulatory approval

• BP+ and BP+ Reporter are currently in process for global regulatory approvals with new distributors currently being appointed worldwide

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “This is another major territory covered by new distributors preparing to deliver the innovative Uscom BP+ and BP+ Reporter to market. PMS are experienced master distributors in China and SE Asia and are keen to get sales under way as soon as regional regulations allows. Worldwide we are appointing new distribution to ensure that immediately our regulatory approvals are received we can begin to sell these revolutionary technologies in the market. The patent protected BP+ devices have major application for assessment of hypertension and vascular health, rapidly increasing disease with high social and cost burdens.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications and in sleep medicine.

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specializing in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced hemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, display trend measures over time, analyse blood pressure waveforms and values, and generate patient reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, display trend measures over time, analyse spirometry outputs, and generate patient reports.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au